

CLEVELAND BIOLABS INC  
Form 8-K  
January 04, 2008

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**FORM 8-K  
CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of Report: (Date of earliest event reported): January 4, 2008

**CLEVELAND BIOLABS, INC.**  
(Exact name of registrant as specified in its charter)

|  |  |   |
|--|--|---|
| <b>Delaware</b><br>(State or other jurisdiction<br>of incorporation or organization) | <b>001-12465</b><br>(Commission File Number) | <b>20-0077155</b><br>(I.R.S. Employer<br>Identification Number) |
|--|--|---|

**73 High Street, Buffalo, New York 14203**  
(Address of principal executive offices)

**Registrant's telephone number, including area code: (716) 849-6810**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events**

On January 4, 2008, the Company issued a press release announcing that it was notified by the U.S. Department of Defense that it was not selected for a contract award granted in connection with a U.S. Department of Defense request for proposal relating to medical radiation countermeasures. A copy of the press release is attached as Exhibit 99.1.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits

| <u>Exhibit No.</u> | <u>Exhibit</u>                       |
|--------------------|--------------------------------------|
| 99.1               | Press Release dated January 4, 2008. |

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CLEVELAND BIOLABS, INC.

Date: January 4, 2008

By: /s/ Michael Fonstein

---

Michael Fonstein  
President and Chief Executive Officer

**EXHIBIT INDEX**

| <b><u>Exhibit No.</u></b> | <b><u>Exhibit</u></b>                |
|---------------------------|--------------------------------------|
| 99.1                      | Press Release dated January 4, 2008. |

---